Lv6
1840 积分 2025-03-28 加入
Large scale, prospective screening of EGFR mutations in the blood of advanced NSCLC patients to guide treatment decisions
1天前
已完结
Detection of EGFR mutations in plasma circulating tumour DNA as a selection criterion for first-line gefitinib treatment in patients with advanced lung adenocarcinoma (BENEFIT): a phase 2, single-arm, multicentre clinical trial
1天前
已完结
Dynamic Changes of Circulating Tumor DNA Predict Clinical Outcome in Patients With Advanced Non-Small-Cell Lung Cancer Treated With Immune Checkpoint Inhibitors
1天前
已完结
Monitoring of the presence of EGFR-mutated DNA during EGFR-targeted therapy may assist in the prediction of treatment outcome
1天前
待确认
Evaluation of Clinical Outcomes of Icotinib in Patients With Clinically Diagnosed Advanced Lung Cancer With EGFR-Sensitizing Variants Assessed by Circulating Tumor DNA Testing: A Phase 2 Nonrandomized Clinical Trial
2天前
已完结
Unrevealing the therapeutic benefits of radiotherapy and consolidation immunotherapy using ctDNA-defined tumor clonality in unresectable locally advanced non-small cell lung cancer
2天前
已完结
Clustered Circulating Tumor Cells as a Predictor of Adjuvant-chemotherapy Efficacy in Lung Cancer
4天前
已完结
Potential of Minimal Residual Disease in Guiding Adjuvant Therapy Decisions in Non–Small Cell Lung Cancer
14天前
已完结
Potential of Minimal Residual Disease in Guiding Adjuvant Therapy Decisions in Non-Small Cell Lung Cancer
14天前
已关闭
Potential of Minimal Residual Disease in Guiding Adjuvant Therapy Decisions in Non-Small Cell Lung Cancer
14天前
已关闭
皖公网安备34019202002308
